EP4423062A4 - MODIFIED INDOLE COMPOUNDS - Google Patents
MODIFIED INDOLE COMPOUNDSInfo
- Publication number
- EP4423062A4 EP4423062A4 EP22887993.8A EP22887993A EP4423062A4 EP 4423062 A4 EP4423062 A4 EP 4423062A4 EP 22887993 A EP22887993 A EP 22887993A EP 4423062 A4 EP4423062 A4 EP 4423062A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- indole compounds
- modified indole
- modified
- compounds
- indole
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D209/16—Tryptamines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163273710P | 2021-10-29 | 2021-10-29 | |
| PCT/US2022/047552 WO2023076150A1 (en) | 2021-10-29 | 2022-10-24 | Modified indole compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP4423062A1 EP4423062A1 (en) | 2024-09-04 |
| EP4423062A4 true EP4423062A4 (en) | 2025-08-27 |
Family
ID=86159727
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP22887993.8A Pending EP4423062A4 (en) | 2021-10-29 | 2022-10-24 | MODIFIED INDOLE COMPOUNDS |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20250002478A1 (en) |
| EP (1) | EP4423062A4 (en) |
| JP (1) | JP2024540030A (en) |
| WO (1) | WO2023076150A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL297861A (en) | 2020-05-08 | 2023-01-01 | Psilera Inc | New compositions of pharmaceutical substances and preparations |
| AU2024275806A1 (en) * | 2023-05-24 | 2025-11-20 | Psilera Inc. | Formulations containing tryptamine derivatives and uses thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002079153A1 (en) * | 2001-03-28 | 2002-10-10 | Biocatalytics, Inc. | Method for producing tryptamine derivatives |
| WO2020181194A1 (en) * | 2019-03-07 | 2020-09-10 | University Of Padova | Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic/psychotomimetic dosages and formulations |
| WO2021168082A1 (en) * | 2020-02-18 | 2021-08-26 | Gilgamesh Pharmaceuticals, Inc. | Specific tryptamines for use in the treatment of mood disorders |
| WO2021226416A1 (en) * | 2020-05-08 | 2021-11-11 | Psilera Inc. | Novel compositions of matter and pharmaceutical compositions |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA795239B (en) * | 1978-10-12 | 1980-11-26 | Glaxo Group Ltd | Heterocyclic compounds |
| CA2931345A1 (en) * | 2013-11-24 | 2015-05-28 | Taipei Medical University | Use of indolyl and idolinyl hydroxamates for treating neurodegenerative disorders or cognitive deficits |
-
2022
- 2022-10-24 EP EP22887993.8A patent/EP4423062A4/en active Pending
- 2022-10-24 US US18/689,983 patent/US20250002478A1/en active Pending
- 2022-10-24 JP JP2024525104A patent/JP2024540030A/en active Pending
- 2022-10-24 WO PCT/US2022/047552 patent/WO2023076150A1/en not_active Ceased
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002079153A1 (en) * | 2001-03-28 | 2002-10-10 | Biocatalytics, Inc. | Method for producing tryptamine derivatives |
| WO2020181194A1 (en) * | 2019-03-07 | 2020-09-10 | University Of Padova | Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic/psychotomimetic dosages and formulations |
| WO2021168082A1 (en) * | 2020-02-18 | 2021-08-26 | Gilgamesh Pharmaceuticals, Inc. | Specific tryptamines for use in the treatment of mood disorders |
| WO2021226416A1 (en) * | 2020-05-08 | 2021-11-11 | Psilera Inc. | Novel compositions of matter and pharmaceutical compositions |
Non-Patent Citations (2)
| Title |
|---|
| MALACA SARA ET AL: "Toxicology and Analysis of Psychoactive Tryptamines", INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, vol. 21, no. 23, 12 April 2020 (2020-04-12), XP093014242, DOI: 10.3390/ijms21239279 * |
| See also references of WO2023076150A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024540030A (en) | 2024-10-31 |
| EP4423062A1 (en) | 2024-09-04 |
| WO2023076150A1 (en) | 2023-05-04 |
| US20250002478A1 (en) | 2025-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK4165024T3 (en) | Cyclobutyldihydroquinolinesulfonamide compounds | |
| EP4253377A4 (en) | 5-HETEROARYL-1H-PYRAZOLE-3-AMINE DERIVATIVE | |
| EP4137404A4 (en) | MULTICOPTER | |
| DK4320112T3 (en) | PYRIDINYL-SUBTITUTED OXOISOINDOLINE COMPOUNDS | |
| EP4186256C0 (en) | ADI-HOC NETWORK-SLICE-CROSS-COMMUNICATION | |
| IL310528A (en) | Pyrazolopyridinone compounds | |
| PL4301748T3 (en) | TRIAZOLYL-METHYL SUBSTITUTED ALPHA-D-GALACTOPYRANOSIDE DERIVATIVES | |
| EP4222352A4 (en) | BOLCHER | |
| IL304774A (en) | Improved superlipid derivatives | |
| EP3957265A4 (en) | MICRODRAPED | |
| IL287177A (en) | Chiral indole compounds | |
| EP4423062A4 (en) | MODIFIED INDOLE COMPOUNDS | |
| EP4308572C0 (en) | THIENOPYRIMIDINONE DERIVATIVES | |
| EP4415710A4 (en) | CRYSTALLINE TRYPTAMINE COMPOUNDS | |
| EP4308576C0 (en) | THIAZOLOPYRIMIDINONE DERIVATIVES | |
| EP4154884A4 (en) | ANTI-SARS-COV-2-DURG | |
| EP4137402A4 (en) | MULTICOPTER | |
| DK4396183T3 (en) | SUBSTITUTED S-ALANINATE DERIVATIVES | |
| PT4038149T (en) | ANTI-FULING COMPOUNDS | |
| EP4377462A4 (en) | IMPROVED CRISPR-CAS TECHNOLOGIES | |
| EP4228051A4 (en) | LEAD-ACCUMULATOR | |
| EP4221968C0 (en) | RADIALPRESSE | |
| EP4320989A4 (en) | MR-DC IMPROVEMENTS | |
| IL313590A (en) | compounds | |
| IL312389A (en) | New benzyltryptamine compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20240520 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20250728 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07D 209/16 20060101AFI20250722BHEP Ipc: A61P 25/30 20060101ALI20250722BHEP Ipc: A61P 25/28 20060101ALI20250722BHEP |